Atropine 0.01% Eye Drops for Myopia Control in American Children: A Multiethnic Sample Across Three US Sites

Abstract

Topical atropine eye drops at low concentrations have been shown to slow myopia progression in East Asian studies. This study explored the effect of atropine 0.01% eye drops on controlling myopia progression in a multiethnic cohort of children in the USA. A multicenter retrospective case–control study (n\u2009=\u2009198) quantified the effect of adding nightly atropine 0.01% eye drops to treatment as usual on the progression of childhood (ages 6–15 years) myopia. Cases included all children treated with atropine for at least 1 year. Controls were matched to cases on both age (±\u20096 months) and baseline spherical equivalent refraction (SER) (±\u20090.50 diopters, D) at treatment initiation. The primary endpoint was the average SER myopia progression after 1, 1.5, and 2 years of therapy. A secondary outcome was the percentage of subjects with a clinically significant worsening of myopia, defined as a greater than −\u20090.75 D SER increase in myopia. The average baseline SERs for the atropine (n\u2009=\u2009100) and control (n\u2009=\u200998) groups were similar (−\u20093.1\u2009±\u20091.9 D and −\u20092.8\u2009±\u20091.6 D, respectively) (p\u2009=\u20090.23). The average SER increase from baseline was significantly less for the atropine group than the control group at year 1 (−\u20090.2\u2009±\u20090.8 D compared with −\u20090.6\u2009±\u20090.4 D, p\u2009<\u20090.001) and at year 2 (−\u20090.3\u2009±\u20091.1 D compared with −\u20091.2\u2009±\u20090.7 D, p\u2009<\u20090.001). Secondary analysis at year 2 revealed that 80% of the control group vs. 37% of the atropine group experienced clinically significant worsening myopia of at least −\u20090.75 D (p\u2009<\u20090.001). There were no major safety issues reported in either group. Similar to results reported in Asia, atropine 0.01% eye drops significantly reduced myopia progression in a cohort of US children over 2 years of treatment. Nevakar, Inc. Plain language summary available for this article.